single-chain antibody

single-chain antibody

A synthetic antibody based on a single-chain fragment, which is a fusion protein of the variable regions of the heavy and light chains of immunoglobulins, connected with a short linker peptide of 10–25 amino acids. Single chains are one of the smallest possible formats for recombinant antibodies, and have potential roles as diagnostic tools and therapeutic agents.
References in periodicals archive ?
In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain antibody for treatment of gastrointestinal adenocarcinomas (Poster Session: Immunomodulatory Agents and Interventions, abstract 5625, poster section 31) - Wednesday, April 21 from 8:00 a.
5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragment frameworks.
ESBA105 is a single-chain antibody fragment directed against TNF?
During the last decade combinatorial technologies have enabled the selection of a variety of monoclonal single-chain antibody fragments (scFv) against all types of antigens and epitopes (8-10).
This mechanism of action has been validated by experiments with single-chain antibody fragments containing the antibody binding site (15).
Based on BAC's proprietary single-chain antibody technology called CaptureSelect[R], the products are suitable for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments.
Poster Title: "MCSP/CD3 bispecific single-chain antibody construct engages CD4+
ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and it is being developed initially for ophthalmic indications.
6) used genetic engineering to produce a single-chain antibody fragment (scFv); when this fragment was used in an assay, the assay was much less affected by nonspecific interference than was an assay of comparable design that used the parent antibody.
Enzon's science-focused strategy includes an extensive drug development program that leverages the company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA) technologies.
Potent control of tumor growth by CEA/CD3- bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
ESBA105 is a single-chain antibody fragment directed against TNF-alpha and is developed in ophthalmic and additional inflammatory indications.
Full browser ?